NXLLF yields 200.00% · JNJ yields 2.13%● Live data
📍 NXLLF pulled ahead of the other in Year 1
Combined, NXLLF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXLLF + JNJ for your $10,000?
Nuix Limited provides investigative analytics and intelligence software solutions in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The company offers Nuix Workstation, a solution for processing file formats and source types into meaningful information by capturing the content, metadata, and context; Nuix Discover that provides processing, analytics, and machine learning-powered review in a single platform; and Nuix Investigate, a solution which extracts, correlates, and contextualizes various types of data types, across people, objects, locations, and events. The company also provides Nuix Adaptive Security, monitors, detects, and responds to the threats of enterprises; Nuix Enterprise Collection Center, a solution to collect disk images or selected data from laptops, desktops, servers, enterprise file shares, and Microsoft sharepoint sites to legal, investigation, security, and compliance teams for investigation; Nuix Automation, a web-based multi-user graphical tool that allows to map out complex data processes across various activities and machines; and Nuix NLP, a solution which combines machine learning technologies with a proprietary language model to discover, understand, classify, and quantify text content. It serves corporations, governments, law enforcement industries, law firms, advisories, and service partners. The company was formerly known as Nuix Pty Ltd and changed its name to Nuix Limited in September 2020. Nuix Limited was founded in 2000 and is headquartered in Sydney, Australia.
Full NXLLF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.